Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IL6 | P05231 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29487186 | 1.00 | L3MBTL1 (0.50) | L3MBTL1CD274PDCD1P4HTMBRAF | |
| Cadaverine Tartrate SCHEMBL30529687 | 0.87 | CD274 (0.48) | L3MBTL1CD274PDCD1P4HTMHDAC1 | |
| SCHEMBL2535399 | 0.86 | L3MBTL1 (0.40) | L3MBTL1CD274PDCD1HDAC1MEN1 | |
| SCHEMBL12558344 | 0.84 | L3MBTL1 (0.50) | L3MBTL1CD274PDCD1P4HTMBRAF | |
| SCHEMBL171901 | 0.82 | L3MBTL1 (0.51) | L3MBTL1CD274PDCD1P4HTMBRAF | |
| SCHEMBL18291272 | 0.81 | L3MBTL1 (0.50) | L3MBTL1CD274PDCD1P4HTMBRAF | |
| SCHEMBL20037908 | 0.81 | L3MBTL1 (0.50) | L3MBTL1CD274PDCD1P4HTMBRAF | |
| SCHEMBL3617576 | 0.81 | L3MBTL1 (0.54) | L3MBTL1CD274PDCD1P4HTMHTT | |
| SCHEMBL6508504 | 0.80 | DRD4 (0.64) | HDAC1DRD4 | |
| SCHEMBL7304460 | 0.79 | CYP1A2 (0.54) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114573553-B | Heteroaromatic ring derivative and preparation method and application thereof | 广州六顺生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023155777-A1 | N- [ (6-BROMOPYRIDIN-3-YL) METHYL] -2-METHOXYETHAN-1-AMINE SALTS AND PREPARATION THEREOF | BEIGENE (SUZHOU) CO., LTD. (CN) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023155777-A1 | N- [ (6-BROMOPYRIDIN-3-YL) METHYL] -2-METHOXYETHAN-1-AMINE SALTS AND PREPARATION THEREOF | BEIGENE (SUZHOU) CO., LTD. (CN) | 2023-08-24 | — | — | WO | disclosed |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20230022859-A1 | TREATMENT OF CANCER WITH ANTI-OX40 ANTIBODIES AND MULTI-KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2023-01-26 | — | — | US | disclosed |
| US-20220402936-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | Mirati Therapeutics, Inc. | 2022-12-22 | — | — | US | disclosed |
| US-20220387404-A1 | TREATMENT OF CANCER USING A COMBINATION COMPRISING MULTI-TYROSINE KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BEIGENE, LTD. (KY) | 2022-12-08 | — | — | US | disclosed |
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | WELLMARKER BIO CO., LTD. (KR) | 2022-09-20 | — | — | US | disclosed |
| CN-111295386-B | Thienopyridine derivatives and pharmaceutical compositions containing the same | 伟迈可生物有限公司 | 2022-09-06 | — | — | CN | disclosed |
| EP-4011885-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2022-06-15 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| WO-2009109035-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009026717-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387404-A1 | TREATMENT OF CANCER USING A COMBINATION COMPRISING MULTI-TYROSINE KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | PDCD1, LCK, CD274 | L3MBTL1 2924/4885CD274 3/4885PDCD1 1/4885 |
| US-20230022859-A1 | TREATMENT OF CANCER WITH ANTI-OX40 ANTIBODIES AND MULTI-KINASE INHIBITORS | TNFRSF9, TNFRSF1A, TNFSF11 | L3MBTL1 2199/4885CD274 6/4885PDCD1 44/4885 |
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | MAP4K5, MAP4K2, MAP3K9 | L3MBTL1 4523/4885CD274 4380/4885PDCD1 1389/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | L3MBTL1 3216/4885CD274 2250/4885PDCD1 802/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | L3MBTL1 3690/4885CD274 984/4885PDCD1 1293/4885 |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | KRAS, RET, NRAS | L3MBTL1 4139/4885CD274 3951/4885PDCD1 2061/4885 |
| US-20220402936-A1 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | ABL1, LCK, SRC | L3MBTL1 4819/4885CD274 1403/4885PDCD1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.